All drugs have side effects, so the key is figuring out whether or not the reward is worth the risk. In the majority of drugs that have gained approval, it likely is worth the risk for enough people that it's allowed on the market. It still has to show it's effective, go out of their way to notify patients of the risks, and just because a drug with lots of potential side effects problems gets approved it doesn't mean it will ever sell well.

Leronlimab is pretty unique in how benign it is when taken. It might be that the FDA doesn't believe it, similar to how they have a hard time wrapping their head around its immunomodulation capabilities, covid application, and a host of other things. It's on Cytodyn to make the case that it's everything we all believe it is. Unfortunately, until Cyrus arrived the company did a piss poor job of building its case for LL. Much of that blame lies with Amarex, and we should be getting some cash back as a result.

Maybe people just need to consider this hold period like the arbitration. Cytodyn will come out on the right side in the end, but it's taking time because they have to prove things that weren't ever documented properly in the first place. And they aren't getting the benefit of the doubt with the FDA because they aren't a big pharma company and, at least before Cyrus came aboard, lacked any real connections to those big dogs.

Amazingly, after all the Amarex bullshit and unlucky randomization in trials and delays and fda letters, all of LL's potential is still ahead of us.